Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 114 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Desc)]
Φίλτρα: Συντάκτης is Doumas, Michael  [Clear All Filters]
2017
Raman, V. K., Tsioufis C., Doumas M., & Papademetriou V. (2017).  Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. Curr Treat Options Cardiovasc Med. 19(5), 39.
Imprialos, K., Faselis C., Boutari C., Stavropoulos K., Athyros V., Karagiannis A., et al. (2017).  SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.. Curr Pharm Des. 23(10), 1510-1521.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., & Karagiannis A. I. (2017).  Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 88(3), 249-253.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters.. JAMA Intern Med. 177(9), 1393.
Doumas, M., Tsioufis C., Fletcher R., Amdur R., Faselis C., & Papademetriou V. (2017).  Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension.. J Am Heart Assoc. 6(11), 
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 71, 17 - 32.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.. Metabolism. 71, 17-32.
2018
Imprialos, K. P., Stavropoulos K., & Doumas M. (2018).  Antihypertensive drug treatment: the real-life challenge.. J Clin Hypertens (Greenwich). 20(1), 115-117.
Stavropoulos, K., Imprialos K. P., Doumas M., & Athyros V. G. (2018).  Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. J Clin Hypertens (Greenwich). 20(2), 255-257.
Doumas, M., Imprialos Κ., Stavropoulos K., Reklou A., Sachinidis A., & Athyros V. G. (2018).  Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.. Curr Pharm Des.
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Antza, C., Doundoulakis I., Akrivos E., Stabouli S., Trakatelli C., Doumas M., et al. (2018).  Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score.. Am J Hypertens. 31(11), 1197-1204.
Athyros, V. G., & Doumas M. (2018).  Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.. Curr Vasc Pharmacol. 16(3), 206-208.
Athyros, V. G., Katsiki N., & Doumas M. (2018).  Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.. Curr Vasc Pharmacol. 16(2), 104-106.
Mitsiou, E., Boutari C., Kotsis V., Georgianou E., Doumas M., Karagiannis A., et al. (2018).  Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.. Curr Vasc Pharmacol. 16(4), 393-400.
Doumas, M., Imprialos K. P., & Stavropoulos K. (2018).  Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.. N Engl J Med. 378(10), 967.
Doumas, M., Imprialos K. P., Stavropoulos K., & Athyros V. G. (2018).  Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. J Clin Hypertens (Greenwich). 20(3), 469-471.
Imprialos, K. P., Stavropoulos K., Doumas M., Skalkou A., Zografou I., & Athyros V. G. (2018).  The potential role of statins in treating liver disease.. Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Doumas, M., Katsiki N., & Papademetriou V. (2018).  Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?. Angiology. 69(1), 5-9.
Reklou, A., Doumas M., Imprialos K., Stavropoulos K., Patoulias D., & Athyros V. G. (2018).  Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovasc Med J. 12, 29-40.
Stavropoulos, K., Imprialos K. P., Athyros V. G., & Doumas M. (2018).  Renal resistive index for renovascular hypertension: In the quest of the Holy Grail.. J Clin Hypertens (Greenwich). 20(3), 589-591.
Doumas, M., Stavropoulos K., Imprialos K. P., Athyros V. G., & Karagiannis A. (2018).  Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. J Clin Hypertens (Greenwich). 20(4), 634-636.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2018).  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.. J Clin Hypertens (Greenwich). 20(1), 65-68.
Stavropoulos, K., Imprialos K. P., Stavropoulos N., Bouloukou S., Kerpiniotis G., Dimitriadis K., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.. Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.